TB-500
In stockThymosin β4 (1-43)TB-500 is the name used for synthetic thymosin beta 4, a 43-residue peptide that binds G-actin. Researchers study the parent peptide in cell migration, angiogenesis and wound models.
Supplied as a single-chamber lyophilized vial with a colour-coded cap (Recovery & Repair).
Research literature, not dosing or treatment instructions.
- Thymosin beta 4 is described as the main G-actin sequestering peptide in mammalian tissue and as a mediator of cell migration, proliferation and differentiation. (PMID 14500546, PMID 22074294)
- The actin-binding region of thymosin beta 4 was mapped and tested for angiogenic activity in endothelial-cell and tissue assays. (PMID 14500546)
- In a rat full-thickness wound model re-epithelialisation and wound contraction were measured. (PMID 10469335)
- Reviews describe thymosin beta 4 expression across human organs during development, and its role in kidney glomerular cells. (PMID 38994967)
Add the solvent slowly along the vial wall; swirl gently, never shake. Allow to dissolve fully. Six-step guide with photos →
Concentration calculator only. Enter the mass being calculated; blend components are not added automatically. Products are for in-vitro research.
Refer to the product label and supplier documentation for storage conditions. Lot-specific storage and expiry information is not available here.
Each certificate is published with its lot number.
Questions about TB-500
How much published research is there on TB-500?
The research library's PubMed search for TB-500 returned 1,195 records on 5 October 2026, 138 of them reviews. The library lists 6 studies chosen for what they measured. ClinicalTrials.gov lists 18 registered studies naming TB-500 (checked 5 October 2026).
Is TB-500 an approved medicine?
No centrally authorised medicine containing TB-500 is listed in the EMA medicines database (checked 5 October 2026), and the research material we supply is not a medicine. The EMA medicines database (checked 5 October 2026) lists no centrally authorised medicine naming TB-500 (searched as thymosin beta or timbetasin) as an active substance. National authorisations are not in that dataset. The WADA 2026 list names thymosin beta 4 and its derivatives, with TB-500 as the example. It is supplied for in-vitro laboratory research only, not for human or veterinary use.
Is TB-500 the same as thymosin beta 4?
TB-500 is the name used for synthetic thymosin beta 4, a 43-residue peptide, and the catalog lists the full-length sequence. The primary literature indexes the parent peptide as thymosin beta 4, so the studies cited on this page concern thymosin beta 4.
How does TB-500 differ from BPC-157?
BPC-157 is a 15-residue synthetic peptide described as a partial sequence of a gastric protein. TB-500 is the name used for synthetic thymosin beta 4, a 43-residue actin-binding peptide. They differ in origin, size and literature, and one rat study has compared each with the combination.
How is the identity of TB-500 confirmed on a certificate?
A research-grade certificate of analysis typically reports identity by mass spectrometry and purity by HPLC. The mass result is read against the average molecular weight of 4963.4 Da listed on this page. The research library's guide to reading a certificate explains each field.
What other names is TB-500 published under?
TB-500 is also written Thymosin β4 (1-43), Tβ4, TB 500 and Thymosin beta 4. The catalog lists it under the name TB-500.
Is this product for human use?
No. Peptency products are supplied for in-vitro research only. Not for human or veterinary use, not for diagnosis or therapy.
Where can I find shipping information?
Current shipping rates and delivery information are on the Shipping & payment page, and the rates that apply to your order are shown at checkout.
Often studied with
For research use only. Not for human or veterinary use.
What is TB-500?
TB-500 is the name used for synthetic thymosin beta 4, a 43-residue peptide that binds G-actin. The catalog lists the full-length sequence. The primary literature indexes the parent peptide as thymosin beta 4, so the studies on this page concern thymosin beta 4. We supply TB-500 as a lyophilized vial for in-vitro laboratory research only.
What are the chemical identifiers of TB-500?
TB-500 has the molecular formula C212H350N56O78S, an average molecular weight of 4963.4 Da and CAS number 77591-33-4.
Chemistry checked against PubChem (CID 16132341), 5 October 2026; full chemistry record in the research library.
What does published research on TB-500 cover?
A PubMed search for TB-500 returned 1,195 records on 5 October 2026, 138 of them reviews. Our research library lists 6 of these studies, chosen for what they measured.
- Thymosin beta 4 is described as the main G-actin sequestering peptide in mammalian tissue and as a mediator of cell migration, proliferation and differentiation. (Philp et al., FASEB J, 2003; PMID 14500546; Goldstein et al., Expert Opin Biol Ther, 2012; PMID 22074294)
- The actin-binding region of thymosin beta 4 was mapped and tested for angiogenic activity in endothelial-cell and tissue assays. (Philp et al., FASEB J, 2003; PMID 14500546)
- In a rat full-thickness wound model re-epithelialisation and wound contraction were measured. (Malinda et al., J Invest Dermatol, 1999; PMID 10469335)
- Reviews describe thymosin beta 4 expression across human organs during development, and its role in kidney glomerular cells. (Faa et al., Cells, 2024; PMID 38994967)
Mechanism, every cited study and the regulator records are on the TB-500 page of the research library. Papers are listed by what they measured, not as evidence of any use.
How is TB-500 supplied and stored?
TB-500 is supplied as a lyophilized (freeze-dried) powder in a sealed vial, for in-vitro laboratory research only. Our stated storage condition for the sealed lyophilized vial is 2 to 8 °C. The label and the lot certificate carry the lot-specific storage condition and expiry date.
What is the regulatory status of TB-500?
The EMA medicines database (checked 5 October 2026) lists no centrally authorised medicine naming TB-500 (searched as thymosin beta or timbetasin) as an active substance. National authorisations are not in that dataset.
No SmPC, PIL or PAR document in MHRA Products matches the exact name (checked 5 October 2026).
The WADA 2026 Prohibited List names this substance under S2.3. A WADA entry is a sporting rule, not a statement about legality outside sport.
The WADA 2026 list names thymosin beta 4 and its derivatives, with TB-500 as the example.
A regulator record is information about a database entry. It is not advice and not a statement that any use is lawful or unlawful in any country. How regulators approach research peptides.
Which related research pages and compounds are listed?
- TB-500: chemistry, literature and regulatory status
- TB-500 compared with BPC-157
- Thymosin peptides
- How to read a certificate of analysis
Related compounds in the catalog: